Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.47 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.47 |
| ▸ | FRK | P42685 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 11/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 8/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4729206 | 0.88 | RAF1 (0.47) | MAPK14RAF1BRAFEGLN1 | |
| SCHEMBL4725920 | 0.88 | EGLN1 (0.48) | MAPK14EGLN1NAMPT | |
| SCHEMBL4727464 | 0.85 | RAF1 (0.48) | RAF1BRAF | |
| SCHEMBL4726798 | 0.85 | RAF1 (0.42) | RAF1BRAF | |
| SCHEMBL4728099 | 0.84 | RAF1 (0.41) | MAPK14EPHA3FRKRAF1HSPB1 | |
| SCHEMBL4728995 | 0.84 | RAF1 (0.53) | RAF1BRAF | |
| SCHEMBL4727578 | 0.83 | RAF1 (0.41) | RAF1BRAF | |
| SCHEMBL4729551 | 0.83 | RAF1 (0.41) | RAF1BRAF | |
| SCHEMBL4729070 | 0.83 | IKBKB (0.43) | MAPK14EPHA3FRKRAF1BRAF | |
| SCHEMBL4727412 | 0.83 | RAF1 (0.43) | RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008021388-A1 | HETEROARYL DERIVATIVES AS CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2008-02-21 | — | — | WO | disclosed |